AttayaSuvannasankhaMD

Oncology • Indianapolis, IN

Hematologic Oncology

Assistant Professor, Medicine, Indiana University School of Medicine

Join to view full profile

Dr. Suvannasankha is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Suvannasankha's full profile

Already have an account?

Office
980 West Walnut Street, Rm 312
Indianapolis, IN 46202
Phone+1 317-274-0843

Fax+1 317-274-0936
Is this information wrong?

Education & Training

University at BuffaloFellowship, Hematology and Medical Oncology, 2000 - 2003
Albert Einstein Healthcare NetworkResidency, Internal Medicine, 1997 - 2000
Chulalongkorn University Faculty of MedicineClass of 1996

Certifications & Licensure

IN State Medical License 2003 - 2023
PA State Medical License 1998 - 2000
American Board of Internal Medicine Hematology

Clinical Trials

Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma Start of enrollment: 2005 Jun 01
Terminated
Phase 2
Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2007 Oct 01
Completed
Phase 2
Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma Start of enrollment: 2010 Aug 27
Completed
Phase 1, Phase 2
Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy Start of enrollment: 2013 Sep 01
Terminated
Phase 2
Role of Osteocytes in Myeloma Bone Disease Start of enrollment: 2014 Jul 23
Recruiting
A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma Start of enrollment: 2014 Oct 01
Withdrawn
Phase 2
Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy Start of enrollment: 2021 Dec 06
Recruiting
Phase 2
First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2019 Jan 23
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

3 citations
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.
Adam D Cohen, María-Victoria Mateos, Yael C Cohen, Paula Rodriguez-Otero, Bruno Paiva, Niels W C J van de Donk, Thomas Martin, Attaya Suvannasankha, Kevin C De Braganc...> ;Blood. 2023 Jan 19
1 citations
GFI1-Dependent Repression ofIncreases Multiple Myeloma Cell Survival.
Daniela N Petrusca, Patrick L Mulcrone, David A Macar, Ryan T Bishop, Evgeny Berdyshev, Attaya Suvannasankha, Judith L Anderson, Quanhong Sun, Philip E Auron, Deborah ...> ;Viszeralmedizin 2021 Gemeinsame Jahrestagung Deutsche Gesellschaft Für Gastroenterologie, Verdauungs- Und Stoffwechselkrankheiten. 2022 Feb 2
2 citations
DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma.
Thibaud Prawitz, Rakesh Popat, Attaya Suvannasankha, Grammati Sarri, Rachel Hughes, Feng Wang, Cosmina Hogea, Shannon Ferrante, Boris Gorsh, Jenny Willson, Venediktos ...> ;Advances in Therapy. 2021 Sep 24
1 citations
Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis.
Andreas Nikolaou, Apoorva Ambavane, Anshul Shah, Wenkang Ma, Jon Tosh, Venediktos Kapetanakis, Jenny Willson, Feng Wang, Cosmina Hogea, Boris Gorsh, Ben Gutierrez, San...> ;Expert Review of Hematology. 2021 Sep 20
40 citations
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
Sagar Lonial, Hans C. Lee, Ashraf Badros, Suzanne Trudel, Ajay K. Nooka, Ajai Chari, Al-Ola Abdallah, Natalie S. Callander, Douglas W. Sborov, Attaya Suvannasankha, Ka...> ;Cancer. 2021 Jul 27
321 citations
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Sagar Lonial, Hans C. Lee, Ashraf Badros, Suzanne Trudel, Ajay K. Nooka, Ajai Chari, Al-Ola Abdallah, Natalie S. Callander, Nikoletta Lendvai, Douglas W. Sborov, Attay...> ;Lancet Oncology. 2020 Feb 1
7 citations
Acquired Factor X Deficiency in Patients With Primary Light Chain Amyloidosis
Siroj Dejhansathit, Attaya Suvannasankha> ;Journal of investigative medicine high impact case reports. 2019 Apr 4
1 citations
Multiple 'doughnut' granulomas in a liver transplant patient with CMV reactivation.
Siroj Dejhansathit, Adam M. Miller, Attaya Suvannasankha> ;Case Reports. 2018 Nov 1
8 citations
Acute lymphoblastic leukaemia with osteolytic bone lesions: diagnostic dilemma.
Natthapon Angsubhakorn, Attaya Suvannasankha> ;Case Reports. 2018 Aug 11
3 citations
Cold agglutinin-mediated autoimmune haemolytic anaemia associated with diffuse large B cell lymphoma
Sariya Wongsaengsak, Magdalena Czader, Attaya Suvannasankha> ;Case Reports. 2018 Jul 10
21 citations
The Role of Semaphorin 4D in Bone Remodeling and Cancer Metastasis.
Konstantinos Lontos, Juraj Adamik, Anastasia Tsagianni, Deborah L. Galson, John M. Chirgwin, Attaya Suvannasankha> ;Frontiers in Endocrinology. 2018 Jun 19
1 citations
Testicular plasmacytoma misdiagnosed as orchitis.
Christopher Schiavo, Steven A. Mann, Jesse Mer, Attaya Suvannasankha> ;Case Reports. 2018 Jun 4
2 citations
Multifocal myeloid sarcomas: a rare presentation of AML
Natthapon Angsubhakorn, Attaya Suvannasankha> ;Case Reports. 2017 Oct 4
329 citations
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Ajai Chari, Attaya Suvannasankha, Joseph W. Fay, Bertrand Arnulf, Jonathan L. Kaufman, Jainulabdeen J. Ifthikharuddin, Brendan M. Weiss, Amrita Krishnan, Suzanne Lentz...> ;Blood. 2017 Aug 24
16 citations
Cell Adhesion Molecule CD166 Drives Malignant Progression and Osteolytic Disease in Multiple Myeloma
Linlin Xu, Khalid S. Mohammad, Hao Wu, Colin D. Crean, Bradley Poteat, Yinghua Cheng, Angelo A. Cardoso, Christophe Machal, Helmut Hanenberg, Rafat Abonour, Melissa A....> ;Cancer Research. 2016 Dec 1
Multifocal Gastric Ulcers Caused by Diffuse Large B Cell Lymphoma in a Patient With Significant Weight Loss
Mark A. Gromski, Jennifer L. Peng, Jiehao Zhou, Howard C. Masuoka, Attaya Suvannasankha, Suthat Liangpunsakul> ;Journal of investigative medicine high impact case reports. 2016 Dec 1
3 citations
Consecutive epigenetically-active agent combinations act in ID1-RUNX3-TET2 and HOXA pathways for Flt3ITD+ve AML
Hamid Sayar, Yan Liu, Rui Gao, Mohammad Abu Zaid, Larry D. Cripe, Jill Weisenbach, Katie J. Sargent, Mehdi Nassiri, Lang Li, Heiko Konig, Attaya Suvannasankha, Feng Pa...> ;Oncotarget. 2015 Nov 7
8 citations
Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
Joshua A. Waters, Jesus M. Matos, Michele T. Yip-Schneider, Juan R. Aguilar-Saavedra, Colin D. Crean, Joal D. Beane, Ryan P. Dumas, Attaya Suvannasankha, C. Max Schmidt> ;Surgery. 2015 Oct 1
32 citations
FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells
Attaya Suvannasankha, Douglas R. Tompkins, Daniel F. Edwards, Katarina V. Petyaykina, Colin D. Crean, Pierrick G.J. Fournier, Jamie M. Parker, George E. Sandusky, Shoj...> ;Oncotarget. 2015 Apr 12
23 citations
Role of bone-anabolic agents in the treatment of breast cancer bone metastases
Attaya Suvannasankha, John M. Chirgwin> ;Breast Cancer Research. 2014 Dec 31
29 citations
Tumor-expressed adrenomedullin accelerates breast cancer bone metastasis
Valerie A. Siclari, Khalid S. Mohammad, Douglas R. Tompkins, Holly W. Davis, C. Ryan McKenna, Xianghong Peng, Lisa L. Wessner, Maria Niewolna, Theresa A. Guise, Attaya...> ;Breast Cancer Research. 2014 Dec 2
17 citations
Regulation of ubiquitin-proteasome system-mediated Tip110 protein degradation by USP15
Khalid Amine Timani, Ying Liu, Attaya Suvannasankha, Johnny J. He> ;The International Journal of Biochemistry & Cell Biology. 2014 Sep 1
6 citations
Comparison of an assumption-free Bayesian approach with Optimal Sampling Schedule to a maximum a posteriori Approach for Personalizing Cyclophosphamide Dosing.
José Miguel Laínez, Seza Orcun, Joseph F. Pekny, Gintaras V. Reklaitis, Attaya Suvannasankha, Christopher A. Fausel, Elias Anaissie, Gary Blau> ;Pharmacotherapy. 2014 Apr 1
3 citations
Validation of a novel approach for dose individualization in pharmacotherapy using gabapentin in a proof of principles study.
Gary Blau, Seza Orcun, José Miguel Laínez, Gintaras V. Reklaitis, Attaya Suvannasankha, Chris Fausel, Elias Anaissie> ;Pharmacotherapy. 2013 Jul 1
17 citations
Temozolomide-Mediated DNA Methylation in Human Myeloid Precursor Cells: Differential Involvement of Intrinsic and Extrinsic Apoptotic Pathways
Haiyan Wang, Shanbao Cai, Aaron Ernstberger, Barbara J. Bailey, Michael Z. Wang, Wenjing Cai, W. Scott Goebel, Magdalena Czader, Colin D. Crean, Attaya Suvannasankha, ...> ;Clinical Cancer Research. 2013 May 15
Join now to see all

Press Mentions

Purdue Researchers at Work on Anemia App to Make Detection EasierNovember 30th, 2017
Early Data Indicates New Therapy Is ‘Safe and Effective’ for Cancer Metastases in BonesApril 30th, 2021